GlassScriptPhysician profile
Thomas Archibald Feely
NPI 1477722890
$1,662.68
in general payments reported to CMS, 2019-2025
19 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.75 · 2020: $34.61 · 2021: $14.83 · 2022: $14.39 · 2023: $445 · 2024: $558 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.21 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $291.10 | 2023-2025 | |
| Amgen INC. | $207.85 | 2023-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $134.28 | 2023-2025 | |
| Lilly USA, LLC | $104.03 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.78 | 2023 | Tradjenta, Jardiance |
| Medtronic, INC. | $60.45 | 2025 | Symplicity G3 |
| Abbott Laboratories | $47.61 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $46.07 | 2024 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $39.58 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $39.51 | 2025 | Rexulti |
| Recor Medical INC | $32.64 | 2025 | Paradise Ultrasound Renal Denervation System |
| Xeris Pharmaceuticals, INC. | $24.28 | 2024 | Recorlev |
| Supernus Pharmaceuticals, INC. | $22.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.75 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $16.33 | 2019 | |
| Amarin Pharma, INC. | $14.83 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.39 | 2022 | |
| Glaxosmithkline, LLC. | $14.18 | 2024 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Feely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.